Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.
about
Bevacizumab treatment for advanced breast cancerA Review of Modeling Approaches to Predict Drug Response in Clinical OncologyTime-dependent endpoints as predictors of overall survival in multiple myelomaIncorporating clinical trial data into daily cancer care.Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profileCost-effectiveness of pazopanib in advanced soft-tissue sarcoma in CanadaIn the end what matters most? A review of clinical endpoints in advanced breast cancer.A Weibull multi-state model for the dependence of progression-free survival and overall survival.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyOverall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trialEvolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast CancerProgression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.A joint frailty-copula model between tumour progression and death for meta-analysis.Outcome switching in randomized controlled oncology trials reporting on surrogate endpoints: a cross-sectional analysis.Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.Evaluating and utilizing probability of study success in clinical development.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
P2860
Q27027498-94ADF685-ACD0-4AFF-9A8E-3D2ECB1848DEQ28066777-C414A4C9-A8D6-4241-A0FB-1AF3C7993E51Q30538040-B02B321C-9A2E-4BCC-942D-0BC6F5D8AB72Q30836868-70F9CB54-C6F1-46C9-884F-C13CD16BC2BFQ33516882-F91F5288-A913-440A-910B-3000AD563FB1Q33800697-0FB9C2FF-1E15-42E0-ABE0-2A117668BACFQ33880656-B94E1607-6D92-4D52-B446-27F0E9F2D2A2Q34173294-BBBF90E0-9DF2-4541-9B10-F266D0B0C226Q34637866-D6BD48FF-B9DE-45CD-8369-9FAA6761FBC7Q35584322-2B168FD4-635B-41AD-9DF9-6BBCA362FDE0Q35812284-2FC6242F-A055-4CD5-9B8D-BEE3D4C55573Q35825822-054DB691-EC8B-4885-8D1B-93C4FA83A206Q36349459-6BFCBF33-0D6C-49A2-AE40-246D817423EEQ36694617-E381DA7F-3BA6-406E-9A7F-F42C024648F6Q36738554-A59F304C-6A2E-4703-A77E-7FD03C4F69C5Q37246407-31BAF8D7-0E8D-4FA4-A510-08E3CB86BB80Q37292020-C7C3CBAE-985C-4A4C-8B1D-D0BFBFE100B6Q37573906-DC0694A9-16D2-4E6F-8029-8673176B93CAQ37630084-A535D7A6-F79B-409F-9628-838E872CFFD3Q37760357-88D13DCC-00C3-4260-A263-2BD3761A5150Q37955095-E865F594-8BC9-4416-AF29-D5EA4DB733A5Q38193714-19D5E7AF-7369-4AB4-BF2B-4D65444E1F72Q38259501-C6BE9858-F030-427E-8CA8-D47CA77A1534Q38351470-84C298B5-3332-41D8-91A9-5AF0F8214DFEQ39933767-D7C9E9EE-5B09-477E-8F93-ED03F3AD5C47Q40525129-2C2A1357-7E95-4E25-90D0-FFFE4A23A7FCQ41503758-FCDD2CB8-CB30-4C27-906A-DD9F80DB901BQ41898172-308E36C2-104C-49DB-96EF-2423B8C996BEQ44734913-F034CD34-89E1-419D-92E1-9EADBFC92FCAQ51248269-1BB464B4-2826-4E23-9E5A-766EAB87D641Q53717818-D129C727-3763-44E3-837E-0B0D0B98A84A
P2860
Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Relationship between effects o ...... s of metastatic breast cancer.
@en
type
label
Relationship between effects o ...... s of metastatic breast cancer.
@en
prefLabel
Relationship between effects o ...... s of metastatic breast cancer.
@en
P2093
P2860
P356
P1476
Relationship between effects o ...... s of metastatic breast cancer.
@en
P2093
B Sherrill
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604759
P407
P577
2008-10-28T00:00:00Z
2008-11-18T00:00:00Z